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The use of ÁÅC- and ÁÆC-fatty acid tracers to estimate the
oxidation of plasma fatty acids has been questioned (Heiling
et al. 1991). The appearance of ÁÅCOµ (and ÁÆCOµ) in breath,
coming from the oxidation of fatty acid tracers, is very low
in the first hours of infusion, especially under resting
conditions (Irving et al. 1983). This means that part of the
label is temporarily fixed in metabolic pools in the body.
When, in resting conditions, labelled NaHCO× is infused,
up to 70—90% of the label is recovered implying that only a
minor fraction of the tracer is entrapped in the bicarbonate
pool and COµ fixation reactions (carboxylation and urea
production) (Leijssen & Elia, 1996). Heiling et al. (1991)
suggested that the plasma tracer first had to mix with a
large intracellular fatty acid pool before it would be oxidized
and that this was the main reason for the delayed and
incomplete appearance of ÁÅCOµ (ÁÆCOµ) in the breath.
However, in contrast to Heiling et al. (1991), Sidossis et al.
(1995b) recently showed that part of the tracer accumulated
in products of the tricarboxylic acid (TCA) cycle (glucose,
glutamate and glutamine; Fig. 1). It was claimed that the
fixation of the tracer in these products, together with
fixation in the bicarbonate pool, was the main reason for the
delayed and incomplete appearance of ÁÅCOµ (ÁÆCOµ) in the
breath. They suggested that the amount of this label fixation
can be determined by measuring the ÁÅCOµ production
during infusion of ÁÅC- (or ÁÆC) acetate, because acetate, like
palmitate, is converted to acetyl-CoA and then enters the
TCA cycle before COµ is produced. According to Sidossis et
al. (1995a) a constant value was observed for the acetate
recovery factor between 3 and 4 h after the start of the
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1. The validity of estimations of plasma fatty acid oxidation using tracers has often been
questioned. The appearance of isotopic markers in breath COµ is delayed and incomplete.
Recently suggestions have been made that substantial amounts of tracer are incorporated
into products of the tricarboxylic acid cycle (e.g. glucose, glutamine and glutamate) and that
an acetate correction factor can be used to correct for tracer fixation. In the present study we
investigated whether the appearance of ÁÅCOµ during a separate infusion of [1,2-ÁÅC] acetate
could be used for correction of [U_ÁÅC]palmitate oxidation rates in studies lasting <2 h and
we quantified the appearance of tracer in the glutamine, glutamate and glucose pools of the
body.
2. An infusion of either [1,2-ÁÅC] acetate (0·104 ìmol min¢ kg¢) or [U_ÁÅC]palmitate
(0·013 ìmol min¢ kg¢) was given to eight male subjects and continued for 2 h at rest. In six
subjects the infusion of [1,2-ÁÅC]acetate was repeated to determine reproducibility of the
acetate recovery.
3. Fractional recovery in breath from [1,2-ÁÅC]acetate gradually increased during the infusion
period at rest from 14·1 ± 0·6% at 60 min to 26·5 ± 0·5% at 120 min after the start of the
infusion. Intersubject coefficient of variance was 8·3 ± 0·6% and intrasubject coefficient of
variance of the acetate recovery tests was 4·0 ± 1·5%. After 2 h of [1,2-ÁÅC]acetate infusion,
12·4 ± 0·8 and 10·3 ± 0·9% of infused ÁÅC was incorporated in the glutamine and glutamate
pools, respectively.
4. In conclusion, the [1,2-ÁÅC]acetate recovery factor can be used for correcting the rate of
[U_ÁÅC]palmitate oxidation in infusing studies of 2 h in resting conditions. Failure to use
this recovery factor leads to a substantial underestimation of the rate of plasma free fatty
acid oxidation. The extent of label fixation could largely be explained by accumulation of
tracer carbon in glutamine and glutamate, and the accumulation in glucose is negligible.
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infusion and it was suggested that this steady state value
should be used to correct palmitate oxidation rates. The first
aim of the present study was to investigate whether the
acetate recovery factor can be used during infusions
lasting 2 h maximum, which would allow a shorter and less
demanding infusion period for healthy volunteers and
patients.
Sidossis et al. (1995a) used a simultaneous infusion of ÁÆC-
acetate and ÁÅC-palmitate, so that only one experiment is
needed to quantify and correct the oxidation of the palmitate
tracer. However, the use of radioactive tracers is under
severe limitation in many countries due to medical ethical
considerations (Beckers et al. 1994). This implies that two
separate experiments are needed, one to measure the ÁÅCOµ
production from [U_ÁÅC]palmitate and one to measure the
ÁÅCOµ production from [1,2-ÁÅC]acetate under identical
conditions. However, in that case, the reproducibility of the
acetate recovery factor should be high to obtain a valid
estimate in two separate experiments. Therefore, the second
aim of the present study was to investigate whether the
acetate recovery factor has to be measured in each
individual or whether the mean of a group is representative
for individuals. So, we measured both the intra- and
intersubject coefficient of variation of the acetate recovery
factor in a group of healthy volunteers.
The main TCA cycle products in which label from
[1,2_ÁÅC]acetate and [U_ÁÅC]palmitate may accumulate are
glucose formed in the liver by gluconeogenesis (Marliss et al.
1971), glutamate released by gut and liver and glutamine
formed and released by skeletal muscle (Marliss et al. 1971;
Darmaun et al. 1986; Elia et al. 1989). The final aim of the
present study was to quantify the appearance in time in
these circulating products of the TCA cycle to judge which
process and tissue are most important for tracer fixation




Eight healthy, male volunteers participated: age, 35·1 ± 1·8 years;
height, 1·80 ± 0·03 m; weight, 79·5 ± 5·3 kg; percentage body fat,
22·3 ± 2·6%; with a body mass index ranging from 19 to
30 kg m¦Â. The nature and risks of the experimental procedure
were explained to the subjects, and all subjects gave their written
informed consent. The study was approved by the Ethical
Committee of Maastricht University.
Experimental design
The experiment consisted of two tests separated by a minimum of
1 week to prevent carry over of tracer. Subjects came to the
laboratory at 08.00 h after an overnight fast. Teflon catheters were
inserted in an antecubital vein for isotope infusion and retrogradely
into a contralateral dorsal hand vein for sampling of arterialized
venous blood. After placement of the catheters subjects rested on a
bed and the hand was placed in a hot-box where air was circulated
at 60°C in order to obtain arterialized venous blood. After 30 min
baseline oxygen consumption and carbon dioxide production were
measured and breath and blood samples were collected.
Immediately thereafter, subjects were given an intravenous dose of
0·085 mg kg¢ of NaHÁÅCO× to prime the bicarbonate pool. Then,
at t = 0, a constant intravenous infusion of [U_ÁÅC]palmitate
(0·013 ìmol min¢ kg¢) or [1,2-ÁÅC]acetate (0·104 ìmol min¢ kg¢)
was started and continued for 120 min. These infusion rates led to
an equal amount of ÁÅC-tracer infusion with both palmitate and
acetate. The concentration of palmitate in the infusate was
measured for each experiment, so that the exact infusion rate could
be determined on an analytical gas chromatograph using
heptadecanoic acid as internal standard (see sample analysis). The
palmitate tracer (60 mg of potassium salt of [U_ÁÅC]palmitate,
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Figure 1
Pathway of acetate and palmitate and routes where label can be lost.
99% enriched; Cambridge Isotope Laboratories, Andover, MA,
USA) was dissolved in heated sterile water and passed through a
0·2 ìm filter into 5% warm human serum albumin to make a
0·670 mÒ solution. The acetate concentration was measured in
each infusate with an enzymatic method (Boehringer, Mannheim,
Germany). The acetate tracer (sodium salt of [1,2-ÁÅC] acetate, 99%
enriched; Cambridge Isotope Laboratories) was dissolved in 0·9%
saline. The chemical and isotopic purity (99%) of palmitate and
acetate tracers were checked by ÁH and ÁÅC NMR and gas
chromatography—mass spectrometry (GC—MS). Blood samples were
taken every 30 min, and breath samples every 10 min. Oxygen
consumption (ýOµ) and carbon dioxide production (ýCOµ) were also
measured every 10 min. In six subjects the acetate test was
repeated to determine the intrasubject reproducibility of the
measurements.
Oxygen consumption and carbon dioxide production were
measured using open circuit spirometry (Oxycon-â, Mijnhardt,
Bunnik, The Netherlands). No changes in oxygen consumption,
carbon dioxide production and respiratory quotient occurred during
the last hour of the resting period and therefore measurements
were averaged for the last hour of the resting period
(t = 60—120 min).
Diet and activity prior to testing
Subjects were asked to fill in a 3 day food intake and activity record
prior to the first test. In the other tests they were asked to repeat
their activity schedule and eat the same food, making sure the diet
was similar in the two tests. Also, subjects were asked not to
consume any products with a high natural abundance of ÁÅC
(carbohydrates derived from C4 plants: maize, sugar cane) 1 week
before and during the entire experimental period.
Body composition
After an overnight fast, body density was determined by
underwater weighing in the fasted state. Body weight was measured
with a digital balance accurate to 0·01 kg (Sauter, type E1200,
Ebungen, Germany). Lung volume was measured simultaneously
with the helium dilution technique using a spirometer (Volugraph
2000, Mijnhardt). Body fat percentage was calculated using the
equations of Siri (1956). Fat-free mass (FFM) in kilograms was
calculated by subtracting fat mass from total body mass.
Sample analysis
Oxygen saturation (Hemoximeter OSM2, Copenhagen, Denmark)
was determined immediately after sampling in heparinized blood.
Fifteen millilitres of arterialized venous blood was sampled in
tubes containing EDTA to prevent clotting and immediately
centrifuged at 3000 r.p.m. (1000 g) for 10 min at 4°C. Plasma was
frozen in liquid nitrogen and stored at −80°C until further
analysis. Plasma substrates were determined using the hexokinase
method for glucose (Roche, Basel, Switzerland) and the Wako
NEFA C test kit for free fatty acids (Wako Chemicals, Neuss,
Germany). Plasma for the analysis of glutamine and glutamate was
deproteinized with 0·3 Ò perchloric acid (PCA) and analysed
enzymatically for glutamate with glutamate dehydrogenate
performed on a COBAS FARA analyser (Roche, Basel, Switzerland).
Glutamine concentration was subsequently determined by converting
glutamine to glutamate using glutaminase.
Breath samples were analysed for ÁÅCÏÁÂC ratio using a gas
chromatography—isotope ratio mass spectrometry system (GC—
IRMS; Finnigan MAT 252, Bremen, Germany). Plasma glutamine
and glutamate tracerÏtracee ratio (TTR) was determined as the N-
methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTBSTFA)
derivative using GC—IRMS. The resulting derivative contains
twenty-three carbon atoms of which five are labelled; TTR is
therefore corrected by the factor 23Ï5. For determination of plasma
palmitate, free fatty acids (FFAs) were extracted from plasma,
isolated by thin-layer chromatography, and derivatized to their
methyl esters. Palmitate concentration was determined on an
analytical gas chromatograph with flame ionization detection using
heptadecanoic acid as internal standard and on average it comprised
24 ± 1% of total FFAs. Isotope tracerÏtracee ratio of palmitate
was determined using GC—IRMS and corrected for the extra methyl
group in its derivative. For determination of the plasma glucose
tracerÏtracee ratio, the glucose was extracted with chloroform—
methanol—water and derivatization occurred with butylboronic acid
and acetic anhydride as described before (Pickert et al. 1991). The
resulting derivative contains sixteen carbon atoms of which six are
labelled; TTR is therefore corrected by the factor 16Ï6.
Calculations
ÁÅC enrichment of breath COµ and plasma metabolites is given in
the form of the tracerÏtracee ratio (TTR). TTR was defined as
(ÁÅCÏÁÂC)sa − (ÁÅCÏÁÂC)bk, in which sa indicates sample and bk
indicates background.
Total carbohydrate and fat oxidations were calculated using
stoichiometric equations (Peronnet & Masssicotte, 1991):
Total fat oxidation = 1·695ýOµ − 1·701ýCOµ,
Total carbohydrate oxidation = 4·585ýCOµ − 3·226ýOµ,
with ýOµ and ýCOµ in litres per minute and total fat and carbohydrate
oxidations in grams per minute.
Total fatty acid oxidation was determined by converting the rate of
total fat oxidation to its molar equivalent, with the assumption that
the average molecular weight of triglyceride is 860 g mol¢, and
multiplying the molar rate of triglyceride oxidation by three
because each molecule contains three fatty acid residues.
Fractional recovery of label (as a percentage) in breath COµ, derived
from the infusion of labelled palmitate or acetate was calculated as
follows:
Fractional recovery of label = (TTRCOµ ² ýCOµ)ÏF ² 100,
where TTRCOµ is tracerÏtracee ratio (TTR) in breath COµ, ýCOµ is
carbon dioxide production (mmol min¢) and F is infusion rate
(mmol min¢).
Breath ÁÅCOµ production, corrected for acetate recovery, during
[U_ÁÅC]palmitate infusion was calculated as:
Corrected ÁÅCOµ production = (TTRCOµ ² ýCOµ)Ïar,
where TTRCOµ is tracerÏtracee ratio (TTR) in breath COµ, ýCOµ is
carbon dioxide production (mmol min¢) and ar is fractional acetate
recovery.
The rate of [U_ÁÅC]palmitate oxidation (ìmol min¢) was calculated
as follows:
Palmitate oxidation = (TTRCOµ ² ýCOµ)Ï(TTRp ² ar) ² 1000,
where TTRp is the tracerÏtracee ratio of fatty acid carbon in
plasma and ar is the fractional acetate recovery.
Total plasma fatty acid oxidation was then calculated by dividing
palmitate oxidation rate by the fractional contribution of palmitate
to the total FFA concentration.
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Rate of appearance (Ra, ìmol min¢) of palmitate in plasma, which
under steady state conditions is equal to the rate of disappearance
(Rd) minus tracer infusion rate, was calculated as:
Ra = F (TTRiÏTTRp),
where TTRi is the tracerÏtracee ratio of fatty acid carbon in
infusion. Percentage of plasma FFA cleared from the circulation
that was oxidized (%Ra oxidized) was calculated as:
% Ra oxidized = plasma FFA oxidationÏRa FFA.
To estimate the amount of infused ÁÅC incorporated in the
glutamine, glutamate and glucose pools it was assumed that the
tracerÏtracee ratio in plasma at the end of the infusion period was
in equilibrium with the respective body pools. Using available data
on the size of the glutamine and glutamate pools, the amount of
infused ÁÅC incorporated in the glutamine and glutamate pools
could then be calculated, by multiplying the plasma enrichment
with the body pool size, as follows:
% ÁÅC incorporated in glutamine =
(TTRglutamine,120 ² 5·369 ² BW)Ï(F ² 120) ² 100,
and
% ÁÅC incorporated in glutamate =
(TTRglutamate,120 ² 1·247 ² BW)Ï(F ² 120) ² 100,
where TTRglutamine,120 and TTRglutamate,120 are tracerÏtracee ratio
of plasma glutamine and glutamate, respectively, at t = 120 min,
5·369 and 1·247 is the size of the glutamine and glutamate pools,
respectively (mmol kg¢) (Darmaun et al. 1986), BW is body weight,
and F is infusion rate (mmol min¢).
For glucose there is inconsistency about the true volume of
distribution. Therefore, a minimal and maximal estimation of the
amount of infused ÁÅC incorporated in the glucose pools was
calculated as follows:
% ÁÅC incorporated in glucose =
(TTRglucose,120 ² 40 ² Concglucose ² BW)Ï(F ² 120) ² 100,
and
% ÁÅC incorporated in glucose =
(TTRglucose,120 ² 200 ² Concglucose ² BW)Ï(F ² 120) ² 100,
where TTRglucose,120 is tracerÏtracee ratio of plasma glucose at
t = 120 min, 40 and 200 are the minimum and maximum volume
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Figure 2
Breath ÁÅCOµ tracerÏtracee ratio (A) and fractional label recovery (%) in breath COµ (B) when infusing
either [1,2-ÁÅC]acetate or [U_ÁÅC]palmitate.
of distribution of glucose (ml kg¢), Concglucose is the average glucose
concentration (t = 90—120 min, mmol l¢), BW is body weight and
F is infusion rate (mmol min¢).
Statistical analysis
To examine if there were individual differences in increase in
acetate recovery factor, linear regression lines were determined for
the period of t = 60 to t = 120 min and slopes and intercepts were
tested using analysis of covariance (ANCOVA). The coefficient of
variance (CV) was calculated as s.d.Ïmean ² 100. All data are
presented as means ± s.e.m. and P < 0·05 is considered as
significance level.
RESULTS
Breath ÁÅCOµ tracerÏtracee ratio gradually increased during
the infusion period both when infusing palmitate and when
infusing acetate (Fig. 2A). No plateau was reached at the
end of the 2 h infusion period.
Fractional label recovery (as a percentage) in breath COµ of
[U_ÁÅC]palmitate increased in a linear way (slope,
0·056% min¢; rÂ, 0·99) from 5·1 ± 0·2% at t = 60 min to
8·4 ± 0·4% at t = 120 min. Fractional label recovery in
breath COµ from [1,2-ÁÅC]acetate also increased in a linear
way (slope, 0·20% min¢; rÂ, 0·99) during the infusion
period from 14·1 ± 0·6% at t = 60 min to 26·5 ± 0·5% at
t = 120 min (Fig. 2B). With acetate, there were no
significant differences in slopes of the linear regression lines
between subjects, but the intercept was significantly different
between subjects (P < 0·05).
Percentage difference (percentage of maximal value) in the
fractional recovery in breath COµ from [1,2-ÁÅC]acetate
between subjects ranged from 15·1 to 32·9% at different
time points. This resulted in a mean intersubject coefficient
of variation of 8·3 ± 0·6%.
Reproducibility
In six subjects, the determination of the acetate recovery
factor was repeated after 2—4 weeks. There were no
significant differences in fractional acetate recovery between
the first and second test at any time point. Intraclass
correlation coefficient between test 1 and test 2 was 0·985
(rÂ = 0·97, P < 0·0001). Percentage difference (percentage
of maximal value) in the fractional recovery in breath COµ
from [1,2-ÁÅC]acetate between two tests in the same subject
ranged from 0·1 to 14·0%, with an average of 5·4%. Mean
intrasubject coefficient of variation over the whole infusion
period was 4·0 ± 1·5%.
Plasma substrate tracerÏtracee ratio
Plasma palmitate tracerÏtracee ratio reached a plateau after
30 min of rest (Fig. 4A) but ÁÅCOµ production, corrected for
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Figure 3
Breath ÁÅCOµ production corrected for recovery when infusing either [1,2-ÁÅC]acetate or [U_ÁÅC]palmitate.
––––––––––––––––––––––––––––––––––––––––––––––
Table 1. Plasma (tracers) and total (indirect calorimetry) fatty acid kinetics for the last
hour of [U-ÁÅC]palmitate infusion
––––––––––––––––––––––––––––––––––––––––––––––
Plasma fatty acid Percentage Total fatty acid
oxidation Ra Ra oxidized oxidation
(ìmol kg¢ min¢) (ìmol kg¢ min¢) (%) (ìmol kg¢ min¢)
––––––––––––––––––––––––––––––––––––––––––––––
No correction 0·56 ± 0·05 7·32 ± 0·31 7·6 ± 0·4 3·83 ± 0·28
Acetate correction 2·43 ± 0·17 7·32 ± 0·31 33·1 ± 1·6 3·83 ± 0·28
––––––––––––––––––––––––––––––––––––––––––––––
Values are means ± s.e.m. for 8 volunteers.
––––––––––––––––––––––––––––––––––––––––––––––
recovery, reached a plateau during the last hour of infusion
(Fig. 3). Therefore, substrate kinetics were averaged over the
last hour. Plasma FFA concentration was 416·8 ±
26·4 ìmol l¢ and plasma palmitate concentration was
100·5 ± 8·1 ìmol l¢ (24 ± 1% of FFA).
Isotopically determined plasma FFA oxidation (Fig. 4B),
rate of appearance (Ra) and percentage of rate of appearance
oxidized are given in Table 1, both with and without using
the acetate correction factor. Using the acetate correction
factor, Ra of FFA was 7·32 ± 0·31 ìmol kg¢ min¢.
Plasma FFA oxidation was 2·43 ± 0·17 ìmol kg¢ min¢
(= 33·1 ± 1·6% of Ra).
Plasma glutamine concentration was 539 ± 13 and 531 ±
14 ìmol l¢ when given palmitate and acetate, respectively.
Glutamine tracerÏtracee ratio gradually increased during
both palmitate and acetate infusion and did not reach a
plateau after the 120 min of rest. The TTR at t = 120 min
was 0·000101 and 0·000544 after palmitate and acetate
infusion, respectively (Fig. 5A).
Plasma glutamate concentration was 83 ± 9 and 76 ±
6 ìmol l¢ after palmitate and acetate infusion, respectively.
Glutamate tracerÏtracee ratio gradually increased during
both palmitate and acetate infusion and did not reach a
plateau after the 120 min of rest. The TTR at t = 120 min
was 0·000386 and 0·001946 after palmitate and acetate
infusion, respectively (Fig. 5B).
Plasma glucose concentration was 4·9 ± 0·1 and
5·1 ± 0·1 mmol l¢ after palmitate and acetate infusion,
respectively. Glucose tracerÏtracee ratio gradually increased
during both palmitate and acetate infusion and did not
reach a plateau after 120 min of rest. The TTR at
t = 120 min was 0·0000214 ± 0·0000017 and 0·0000928 ±
0·0000084 after palmitate and acetate infusion, respectively
(Fig. 5C).
DISCUSSION
The results of the present study demonstrate that the
acetate recovery factor can be used to correct palmitate
oxidation rates in infusion studies of 2 h or less. However, to
correct palmitate oxidation rates, the acetate recovery
factor needs to be determined for every time point, because
the fractional label recovery in breath COµ of both
[U_ÁÅC]palmitate and [1,2-ÁÅC]acetate increased in a linear
way.
The present study demonstrates a good reproducibility for
the acetate recovery factor. Intrasubject coefficient of
variation was 4·0%. However, this does not guarantee that
in any given individual the acetate recovery factor can be
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Figure 4
ÁÅC-palmitate tracerÏtracee ratio (A) and plasma FFA oxidation
calculated using acetate correction factor (B) when infusing
[U_ÁÅC]palmitate.
determined in a separate experiment. Therefore the range in
percentage difference in individual subjects between the two
tests at different time points is more important. The
maximum difference found within one subject between the
two tests at any time point was 14·0%. The mean difference
between the two tests was 5·4%. These results show that it
is valid to estimate the fractional recovery in a separate
experiment, making it possible to use ÁÅC-labelled acetate to
determine the correction factor needed to correct the plasma
FFA oxidation data.
To study whether it is necessary to determine the acetate
correction factor in each individual the intersubject coefficient
of variance was calculated. The intersubject coefficient of
variance was 8·3 ± 0·6%, with a percentage difference
between subjects ranging from 15·1 to 32·9% at different
time points. This means that an individual estimation of the
recovery of ÁÅC-acetate is needed. Using one average recovery
factor for a group as a whole can lead to over- or under-
estimation of fatty acid oxidation of more than 30% in
individual subjects.
One possible pathway for label fixation is the loss of ÁÅC from
the TCA cycle in the form of glutamate and glutamine. The
label is then stored in the glutamine and glutamate pools,
which are in equilibrium with plasma glutamine and
glutamate. We found a gradual increase in both glutamine
and glutamate tracerÏtracee ratio in plasma. This implies
that the tracerÏtracee ratio of the intracellular glutamine
and glutamate pools will also gradually increase. Once the
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Figure 5
ÁÅC glutamine tracerÏtracee ratio (A), ÁÅC glutamate
tracerÏtracee ratio (B) and ÁÅC glucose tracerÏtracee ratio
(C) when infusing either [1,2-ÁÅC]acetate or
[U_ÁÅC]palmitate.
intracellular glutamine and glutamate pools increase in
tracerÏtracee ratio, more tracer will be recovered after
oxidation of these pools. Indeed, in our experiment, we did
not reach a steady state in breath ÁÅCOµ tracerÏtracee ratio
at the end of the 2 h infusion period. ÁÅCOµ tracerÏtracee
ratio increased in a linear way. As long as the glutamine/
glutamate tracerÏtracee ratio has not reached a plateau, the
amount of recycling of ÁÅC will increase and therefore breath
ÁÅCOµ tracerÏtracee ratio will increase. Considering the large
glutamineÏglutamate pools in muscle, it is not to be expected
that during a 2 h infusion period an isotopic steady state can
be derived. Furthermore, Van Acker et al. (1996) showed
that no isotopic steady state in both plasma and muscle
glutamine tracerÏtracee ratio was obtained after 11 h of
infusion of labelled glutamine. Wolfe & Jahoor (1990) also
showed a gradually increasing ÁÅCOµ production for a period
of 4 h. In contrast, Sidossis et al. (1995a) reported an
apparent plateau in breath ÁÅCOµ tracerÏtracee ratio at the
end of 3 h of infusion at rest. However, they also reported
an increase in glutamine tracerÏtracee ratio which had not
reached a plateau at the end of the infusion period. The
extracellular glutamine pool has been estimated to be
110 ìmol kg¢, the intracellular muscle glutamine pool to be
5200 ìmol kg¢ and the intracellular liver glutamine pool to
be 39 ìmol kg¢ (Darmaun et al. 1986). Using these figures,
and assuming that the plasma glutamine tracerÏtracee ratio
at the end of the 2 h infusion period is in equilibrium with
the muscle glutamine tracerÏtracee ratio, it can be estimated
that 12·4 ± 0·8% of infused ÁÅC was incorporated in the
glutamine pools after 2 h of [1,2-ÁÅC]acetate infusion. The
same estimation can be performed for the glutamate pools,
considering an extracellular glutamate pool of 7 ìmol kg¢,
an intracellular liver free glutamate pool of 40 ìmol kg¢ and
intracellular muscle glutamate pool of 1200 ìmol kg¢
(Darmaun et al. 1986), resulting in 10·3 ± 0·9% of infused
ÁÅC incorporated in the glutamate pools. It should be kept in
mind that these calculations reflect the minimal amount of
tracer that is incorporated in the glutamine and glutamate
pools as it may well be possible that after 2 h of infusion the
ÁÅC tracerÏtracee ratio of glutamine and glutamate at the
endogenous production site is higher than the plasma tracer/
tracee ratio. Thus the loss of ÁÅC from the TCA cycle in the
form of glutamate and glutamine contributes significantly to
the low recovery of acetate at rest.
Another possible pathway for label fixation is the loss of ÁÅC
from the TCA cycle to glucose in gluconeogenic pathways. In
our experiment the glucose tracerÏtracee ratio gradually
increased. When only the plasma volume (40 ml kg¢) is
considered as the volume of distribution for glucose, it can be
calculated that 0·06 ± 0·09% of infused ÁÅC is incorporated
in the glucose pools. When the total extracellular fluid is
assumed to be 0·2 l kg¢ (Darmaun et al. 1986) these
figures become 0·32 ± 0·04%. There is some discrepancy
about the true distribution volume of glucose, but the true
value will be somewhere between these two figures. Thus it
can be concluded that the loss of ÁÅC to glucose is negligible.
This also means that gluconeogenesis contributes only little
to label fixation and forms a minor component of the
acetate recovery factor in post-absorptive subjects in resting
conditions. Label fixation in glutamine and glutamate from
a quantitative point of view is more important.
In our experiment, recovery of uniformly labelled acetate
was ±27% at the end of the 2 h infusion period. These
figures are far less than the results obtained by Sidossis et al.
(1995a). They found an acetate recovery of 56% at the end
of a 3 h infusion period at rest. In our experiment, the
recovery increased in a linear way and extrapolation to 3 h
results in an acetate recovery of 38%. This is still less then
the recovery found in the study of Sidossis et al. (1995a).
However, Sidossis et al. (1995a) used ÁÆC-acetate, which was
labelled in the (C-1) position, while in our experiment
acetate was uniformly labelled (C-1 and C-2). The effect of
the position of the labelled carbon atom on percentage
recovered label was studied by Wolfe & Jahoor (1990). After
a 4 h infusion period 81% of infused [1-ÁÅC]acetate was
recovered, while only 53% of [2-ÁÅC]acetate was recovered.
The difference in tracer position therefore may explain a
major part of the difference in acetate recovery found
between our study and the study of Sidossis et al. (1995a).
The acetate correction factor had to be determined using
uniformly labelled acetate because it was used to correct the
oxidation rate of [U_ÁÅC]palmitate. A major reason for use
of [U_ÁÅC]palmitate is that only one-sixteenth of the dose of
[1-ÁÅC]palmitate tracer is required to get an equivalent
amount of ÁÅCOµ production. A major practical limitation
with the use of palmitate tracers is the low solubility in
aqueous solutions. For this reason palmitate is infused
bound to human albumin. In case of the [1-ÁÅC]palmitate
tracer the amount of albumin infused is so large that infusion
periods maximally may last 1—2 h (to prevent unacceptable
osmotic shifts in the plasma). This period can be substantially
lengthened when a [U_ÁÅC]palmitate tracer is used. The
amount of fixation of tracer in TCA cycle products will be
larger with [U_ÁÅC]palmitate than with [1_ÁÅC]palmitate but
can be corrected by measuring the breath ÁÅCOµ recovery
from [1,2-ÁÅC]acetate.
The impact of the acetate correction factor is shown in
Table 1. In this table plasma FFA oxidation is shown with
and without applying an acetate correction factor. In our
study, without the correction factor plasma FFA oxidation
at rest is underestimated 4-fold. Using the acetate correction
factor, the calculated plasma fatty acid oxidation was
approximately 66% of total fatty acid oxidation. The
contribution of other fatty acids than those derived from
plasma to energy expenditure in the resting state is
controversial. In their study, Sidossis et al. (1995b) suggest
that, at rest, nearly all fatty acids used for oxidation are
plasma-borne fatty acids. However in another study by
Sidossis et al. (1996) plasma fatty acid oxidation is only
responsible for 80% of total FFA oxidation, leaving 20%
for other tissues (intramuscular oxidation, liver oxidation or
very-low-density lipoprotein (VLDL) oxidation).
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The need to correct oxidation for the recovery of infused
label not only concerns fat metabolism. Because loss of label
occurs in the TCA cycle, the fraction of label which is
recovered should also be determined when studying
carbohydrate and protein metabolism. Recently, it was
shown that during glucose infusion exogenous glucose
oxidation (determined by tracer) accounted for all glucose
oxidation (determined by indirect calorimetry) when the
acetate recovery factor was applied, whereas when only
using a bicarbonate correction factor (i.e. 0·8; Bonadonna
et al. 1990) endogenous glycogen oxidation contributed
substantially to total glucose oxidation (Tounian et al. 1996).
These studies indicate the importance of the recovery factor
in studying oxidation rates of ÁÅC-enriched substrates
especially at rest.
In conclusion, the [1,2-ÁÅC]acetate recovery factor can be
used for correcting the rate of [U_ÁÅC]palmitate oxidation in
infusing studies of 2 h in resting conditions. Intrasubject
coefficient of variation was small, which makes it possible to
determine the acetate recovery factor in a second separate
experiment using [ÁÅC]acetate in one experiment and
[ÁÅC]palmitate in the other. However, the acetate recovery
factor should be determined in each individual and for every
time point, because the acetate recovery increases with
time. From a quantitative point of view accumulation of
tracer carbon in glutamine and glutamate seems much more
important to explain the label fixation than accumulation in
glucose released by the liver. Failure to correct for the low
acetate recovery under these conditions leads to dramatic
underestimation of the oxidation rate of plasma fatty acid
tracers. Therefore, most previous estimates of plasma
fatty acid oxidation published in the literature are major
underestimations.
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